Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 750 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now owns 2,926 shares of the company’s stock, valued at $125,291.32. This represents a 20.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.10, for a total value of $117,750.00.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM opened at $42.00 on Thursday. The business’s 50-day simple moving average is $42.86 and its two-hundred day simple moving average is $40.61. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $48.89. The stock has a market cap of $2.02 billion, a PE ratio of -20.79 and a beta of 0.98. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. During the same quarter last year, the company earned ($0.57) EPS. The firm’s quarterly revenue was up 89.4% on a year-over-year basis. As a group, analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on MIRM shares. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Citigroup lifted their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners raised their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, Robert W. Baird boosted their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $57.10.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp increased its holdings in Mirum Pharmaceuticals by 19.9% in the 3rd quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after acquiring an additional 297,511 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Mirum Pharmaceuticals by 6.9% in the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock worth $7,854,000 after purchasing an additional 14,843 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Mirum Pharmaceuticals by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock worth $12,798,000 after buying an additional 17,149 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Mirum Pharmaceuticals by 3.2% in the third quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock worth $36,519,000 after buying an additional 29,017 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Mirum Pharmaceuticals by 48.2% during the second quarter. Bank of New York Mellon Corp now owns 143,000 shares of the company’s stock valued at $4,889,000 after buying an additional 46,506 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.